Abstract
Carboplatin (CBDCA) is classified as a moderate emetic risk but is a higher risk than other chemotherapy agents. Therefore, a three-drug prophylactic antiemetic regimen is recommended comprising a 5-hydroxytryptamine type-3 receptor antagonist (5-HT3 RA), dexamethasone, and a neurokinin-1 receptor antagonist (NK1 RA). Olanzapine (OLZ) is lower cost than NK1 RA and more effective in controlling nausea. This phase II study aimed to investigate the efficacy and safety of a low dose of 5 mg OLZ in combination with 5-HT3 RA and dexamethasone for CBDCA-induced nausea and vomiting in patients with thoracic malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
